Renin Activity, Plasma, Three Specimens
Use
Renin Activity, Plasma, Three Specimens test is primarily used to evaluate the activity of renin in plasma. This measurement is critical in assessing renal function, managing hypertension, and evaluating various conditions related to fluid and electrolyte balance. Elevated or decreased renin activity can indicate issues like renovascular hypertension, primary hyperaldosteronism, and chronic kidney disease. The test provides valuable data in diagnosing and managing these conditions by helping healthcare providers understand the underlying physiological process driving the patient’s symptoms. This test is significant for tailoring medication and treatment strategies to achieve optimal patient outcomes.
Special Instructions
This test involves multiple specimens collected at different time points, typically involving a baseline sample followed by additional samples after a specific treatment is administered, like a drug or intake of glucola. It is important to coordinate closely with the attending clinician before collection, as the test requires specific protocols to be followed. If treatment is not planned between samples, another test should be considered. Also, it is crucial to refer to the Endocrine Appendix of the LabCorp Directory of Services for complete instructions on multiple specimen testing.
Limitations
The Renin Activity, Plasma test is subject to limitations inherent in its methodology and the physiological variability of the renin-angiotensin system, which can be influenced by factors such as posture, medications, diet, and time of day. Additionally, the interpretative value can be affected if the patient is not properly prepared or if the specimen handling does not adhere to the specified protocols. External factors like hemolysis or sample contamination can also affect results. The test requires precise timing for sample collection and administration of any therapeutic agents, necessitating strict adherence to the described procedure to ensure accurate results. The test has not been cleared or approved by the FDA, which may affect its acceptance in certain clinical settings.
Methodology
Other
Biomarkers
LOINC Codes
- 17515-8
- 25513-3
- 12900-7
Result Turnaround Time
4-7 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided
Container
EDTA plasma specimen
Collection Instructions
Collect three specimens. Initial tube (baseline), followed by samples after administering treatment or glucola.
Storage Instructions
Keep the samples frozen for optimal analysis. Delay in freezing or improper handling may invalidate the test results.
Causes for Rejection
Rejection causes include non-frozen samples, non-separated samples, non-EDTA plasma specimens, and gross icterus.